While the Genzyme acquisition has allowed Sanofi ( SNY ) to increase its presence in the biopharmaceutical market, we note …read more
Update on Sanofi’s Fabrazyme Manufacturing – Analyst Blog
- by Bob Mitchell
While the Genzyme acquisition has allowed Sanofi ( SNY ) to increase its presence in the biopharmaceutical market, we note …read more